Kintz Samuel's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jul 21, 2025
- Accession no.
- 0001415889-25-020087
- Filed
- Jul 21, 2025
- Trade date
- Jul 17, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $281.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kintz SamuelCIK 0001967168 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 17, 2025 | Common Stock | SSaleDisposed | −4,150 | $21.58 | −$89,557 | 948,742 | Indirect | |
| Jul 17, 2025 | Common Stock | SSaleDisposed | −4,687 | $22.69 | −$106,348.03 | 944,055 | Indirect | |
| Jul 17, 2025 | Common Stock | SSaleDisposed | −3,663 | $23.37 | −$85,604.31 | 940,392 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.